Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2007 1
2008 2
2009 2
2010 4
2011 8
2012 5
2013 3
2014 4
2015 4
2016 2
2017 2
2018 3
2019 4
2020 2
2021 5
2022 4
2023 3
2024 8
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.
Röth A, Fu R, He G, Alzahrani H, Chou SC, Hicheri Y, Kaźmierczak M, Recova VL, Uchiyama M, Vladareanu AM, Beveridge L, Buatois S, Buri M, Compagno N, Shi D, Balachandran N, Sreckovic S, Scheinberg P. Röth A, et al. Among authors: vladareanu am. Eur J Haematol. 2025 Feb;114(2):373-382. doi: 10.1111/ejh.14339. Epub 2024 Nov 13. Eur J Haematol. 2025. PMID: 39535306 Free PMC article. Clinical Trial.
Dominance of mutations in epigenetic regulators and a diversity of signaling alterations in blast-phase BCR::ABL1-negative myeloproliferative neoplasms.
Gurban P, Mambet C, Botezatu A, Necula LG, Matei L, Neagu AI, Pitica I, Ataman M, Tatic A, Bardas A, Gaman MA, Dobrea C, Dragomir M, Ghimici C, Angelescu S, Barbu D, Stanca O, Danila M, Berbec N, Colita A, Vladareanu AM, Nedeianu S, Chivu-Economescu M, Bleotu C, Coriu D, Sepulchre E, Anton G, Diaconu CC, Constantinescu SN. Gurban P, et al. Among authors: vladareanu am. Am J Hematol. 2025 Jan;100(1):168-171. doi: 10.1002/ajh.27503. Epub 2024 Oct 19. Am J Hematol. 2025. PMID: 39425629 No abstract available.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
65 results